Thus, the elevated PD-L1+ tumor-derived exosomes, intratumoral PD-L1+ neutrophils, intratumoral PD-L1+ macrophages, and PD-L1+ tumor cells all have the potential to attenuate the anti-tumor responses elicited by BNT162b2-based cancer therapy. The gene discussed is CD274; the disease is neoplasm.